ClinicalTrials.gg
CompletedNCT05707390Updated Feb 7, 2024

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

A Phase 1 interventional study of Mezigdomide in Hepatic Impairment, sponsored by Bristol-Myers Squibb. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Mezigdomide
  • BMS-986348
  • CC-92480
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Hepatic Impaired Participants:

  • Participants have mild, moderate, or severe hepatic impairment or cirrhosis due to chronic hepatic disease and/or prior alcohol use.
  • Participants have mild (Group A), moderate (Group B), or severe (Group C) hepatic impairment as defined by Score.

Matched Healthy Participants:

  • Participant must be free of any disease that would interfere with the study evaluations.
  • Participant must have liver-related laboratory test results within the respective reference ranges or with clinically insignificant excursions therefrom as agreed by the investigator.

Exclusion criteria

Exclusion Criteria:

All Participants:

  • History of chronic pruritus or dermatologic syndromes that may be confounded with reactions to mezigdomide.
  • or intolerance to first-generation antihistamine medications.

Hepatic Impaired Participants:

-Clinical laboratory test results:

  • count lower than 30,000/microliter (μL) at screening or Day -1.
  • lower than 1,500/μL at screening or Day -1.

Matched Healthy Participants:

-History of or suspected benign ethnic neutropenia.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment

    Drug: Mezigdomide

  • Experimental
    Moderate hepatic impairment

    Drug: Mezigdomide

  • Experimental
    Severe hepatic impairment

    Drug: Mezigdomide

  • Experimental
    Healthy participants

    Drug: Mezigdomide

Interventions

  • Specified dose on specified days

    Also known as: BMS-986348, CC-92480

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 6 days

  2. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-T])

    Time frame: Up to 6 days

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 6 days

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 6 days

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 6 days

  3. Number of participants with physical examination abnormalities

    Time frame: Up to 6 days

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 6 days

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 6 days

  6. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 6 days

  7. Metabolic ratio of AUC(0-T)

    Time frame: Up to 6 days

  8. Metabolic ratio of AUC(0-INF)

    Time frame: Up to 6 days

07

Study locations

3 sites
  • PANAX
    Miami Lakes, Florida 33014, United States
  • Orlando Clinical Research Center OCRC
    Orlando, Florida 32809, United States
  • The Texas Liver Institute
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Sep 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Jan 31, 2023
StartActual
Feb 20, 2023
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05707390
Responsible party
Sponsor
First posted
Jan 31, 2023
Start date
Feb 20, 2023
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Feb 7, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion